Your browser doesn't support javascript.
loading
Identifying low cancer-specific mortality risk lymph node-positive radical prostatectomy patients.
Barletta, Francesco; Tappero, Stefano; Morra, Simone; Incesu, Reha-Baris; Cano Garcia, Cristina; Piccinelli, Mattia L; Scheipner, Lukas; Tian, Zhe; Gandaglia, Giorgio; Stabile, Armando; Mazzone, Elio; Terrone, Carlo; Longo, Nicola; Tilki, Derya; Chun, Felix K H; de Cobelli, Ottavio; Ahyai, Sascha; Saad, Fred; Shariat, Shahrokh F; Montorsi, Francesco; Briganti, Alberto; Karakiewicz, Pierre I.
Affiliation
  • Barletta F; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Tappero S; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Morra S; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Incesu RB; Department of Urology, IRCCS Policlinico San Martino, Genova, Italy.
  • Cano Garcia C; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
  • Piccinelli ML; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Scheipner L; Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
  • Tian Z; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Gandaglia G; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Stabile A; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Mazzone E; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
  • Terrone C; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Longo N; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
  • Tilki D; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Chun FKH; Department of Urology, Medical University of Graz, Graz, Austria.
  • de Cobelli O; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Ahyai S; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Saad F; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Shariat SF; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Montorsi F; Department of Urology, IRCCS Policlinico San Martino, Genova, Italy.
  • Briganti A; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
  • Karakiewicz PI; Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
J Surg Oncol ; 129(7): 1305-1310, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38470523
ABSTRACT

OBJECTIVES:

To identify low cancer-specific mortality (CSM) risk lymph node-positive (pN1) radical prostatectomy (RP) patients.

METHODS:

Within Surveillance, Epidemiology and End Results database (2010-2015) pN1 RP patients were identified. Kaplan-Meier plots and multivariable Cox-regression (MCR) models were used. Pathological characteristics were used to identify patients at lowest CSM risk.

RESULTS:

Overall, 2197 pN1 RP patients were identified. Overall, 5-year cancer-specific survival (CSS) rate was 93.3%. In MCR models ISUP GG1-2 (hazard ratio [HR] 0.12, p < 0.001), GG3 (HR 0.14, p < 0.001), GG4 (HR 0.35, p = 0.002), pT2 (HR 0.27, p = 0.012), pT3a (HR 0.28, p = 0.003), pT3b (HR 0.39, p = 0.009), and 1-2 positive lymph nodes (HR 0.64, p = 0.04) independently predicted lower CSM. Pathological characteristics subgroups with the most protective hazard ratios were used to identify low-risk (ISUP GG1-3 and pT2-3a and 1-2 positive lymph nodes) patients versus others (ISUP GG4-5 or pT3b-4 or ≥3 positive lymph nodes). In Kaplan-Meier analyses, 5-year CSS rates were 99.3% for low-risk (n = 480, 21.8%) versus 91.8% (p < 0.001) for others (n = 1717, 78.2%).

CONCLUSIONS:

Lymph node-positive RP patients exhibit variable CSS rates. Within this heterogeneous group, those at very low risk of CSM may be identified based on pathological characteristics, namely ISUP GG1-3, pT2-3a, and 1-2 positive lymph nodes. Such stratification scheme might be of value for individual patients counseling, as well as in design of clinical trials.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatectomy / Prostatic Neoplasms / SEER Program / Lymph Nodes / Lymphatic Metastasis Limits: Aged / Humans / Male / Middle aged Language: En Journal: J Surg Oncol Year: 2024 Document type: Article Affiliation country: Canada

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatectomy / Prostatic Neoplasms / SEER Program / Lymph Nodes / Lymphatic Metastasis Limits: Aged / Humans / Male / Middle aged Language: En Journal: J Surg Oncol Year: 2024 Document type: Article Affiliation country: Canada